About Ellen ‘t

Ellen ‘t Hoen is a lawyer and public health advocate with over 30 years of experience working on pharmaceutical and intellectual property policies.

From 1999 until 2009 she was the director of policy for Médecins sans Frontières’ Campaign for Access to Essential Medicines. In 2009 she joined UNITAID in Geneva to set up the Medicines Patent Pool (MPP), an initiative that negotiates patent licenses with pharmaceutical companies to ensure access to affordable generic medicines for the treatment of HIV, TB and HCV. Her TED Talk about the Medicines Patent Pool is available here. She was the MPP’s first executive director until 2012.

She has published widely and is the author of several books. Her latest book “Private Patents and Public Health: Changing intellectual property rules for public health.” as published July 2016.

She is a member of the Lancet Commission on Essential Medicines, the Advisory Board of Universities Allied for Essential Medicines (UAEM) and the Editorial Board of the Journal of Public Health Policy.

In 2005, 2006, 2010 and 2011 she was listed as one of the 50 most influential people in intellectual property by the journal Managing Intellectual Property.

Ellen ‘t Hoen is an independent consultant in medicines law and policy to a number of international organisations and governments and a researcher at the Global Health Unit of the University Medical Centre Groningen, The Netherlands.

This speaker will be presenting at the following session(s)

  • Access to treatment

    Panel

    Day: 2 November

    Time: 15:30

    This closing panel session examines how to develop the uninterrupted supply of quality-assured vaccines, medicines, diagnostics and other commodities on which effective hepatitis programmes are dependent.

    Chair: Liudmyla Maistat, Medicines Patent Pool

    Chair: Charles Gore, World Hepatitis Alliance

    Presentations:

    • Introduction to Intellectual Property.
    • Ellen ‘t Hoen, University Medical Centre Groningen
    • Patent opposition.
    • Direct price negotiations.
    • Compulsory licensing.
    • Voluntary licensing.
    • Greg Perry, Medicines Patent Pool
    • Open discussion with audience.

    Objectives:

    • To provide an overview of key IP barriers to access hepatitis C treatment.
    • To review different approaches to overcoming price and IP barriers and the progress made.
    • To discuss the possibility for organisations and civil society groups applying different methods and approaches to scaling up access to hepatitis C treatment to be complementary in their strategies.